<DOC>
	<DOCNO>NCT00920478</DOCNO>
	<brief_summary>Patients rheumatoid arthritis risk develop permanent joint damage disability . This study hop identify effective way use exist arthritis medication minimise chance develop permanent disability . Patients arthritis activity assess use ultrasound machine . If still evidence active arthritis participant 's arthritis medication increase arthritis remission . The effectiveness approach compare traditional method assess arthritis use clinical examination . Furthermore , extremely important identify patient risk aggressive disease . The investigator hope produce accurate measurement disease prognosis examine relationship series blood test well control rheumatoid arthritis appear 18 month therapy . Some patient also ask donate sample joint fluid joint line additional analysis .</brief_summary>
	<brief_title>Targeting Synovitis Early Rheumatoid Arthritis</brief_title>
	<detailed_description>PURPOSE 1 − determine whether possible achieve good control inflammatory joint disease activity early rheumatoid arthritis use musculoskeletal ultrasound , instead clinical examination , identify presence , absence , synovitis NULL HYPOTHESIS 1 − use musculoskeletal ultrasound confirm / refute presence ongoing synovitis NOT allow good control early rheumatoid arthritis prevent progression destructive joint disease despite patient receive intensive disease modify therapy regimen PURPOSE 2 − determine whether baseline measure certain biochemical pathological factor , associate development inflammatory synovitis , predictive response therapy early rheumatoid arthritis short term outcome measure inflammatory joint disease activity , functional ability quality life NULL HYPOTHESIS 2 − serial measure biochemical pathological factor , associate development inflammatory synovitis , NOT correlate short term outcome measure disease activity therefore use predict patient 's prognosis identify risk progressive , destructive joint disease TRIAL DESIGN − randomise , prospective single blind trial treatment strategy nest study correlate baseline measure 18 month outcome Investigators blind treatment group . Treatment decision escalation therapy dictate standardised protocol . The sequence therapy escalation identical group . The group differ threshold need progress next treatment step Assessors disease activity , radiological pathological outcome blind treatment group finding form basis group final outcome measure TREATMENT PROTOCOL − sequence therapy escalation group . The group differ 'trigger ' required progress next treatment step . Therapy escalate group measure disease activity exceed group threshold trigger . Changes DMARD therapy dose and/or combination take three month reach maximum effect ; therefore , least three month gap leave treatment escalation PRIMARY OUTCOME MEASURE 1 . Magnetic Resonance Imaging Dominant Wrist − baseline 18 month . Images score use OMERACT RAMRIS ( Rheumatoid Arthritis Magnetic Resonance Imaging Score ) atlas . The change patient 's synovitis erosion score pool compare intervention group 2 . 44 joint Disease Activity Score - Mean change DAS44 time represent rate response treatment . Mean area curve DAS44 represent overall level disease activity throughout study period SECONDARY OUTCOME MEASURES 1 . European League Against Rheumatism Response Rates − A EULAR Good response define great 1.2 change DAS44 final DAS44 le 2.4 . Disease remission define DAS44 le 1.6 2 . Functional Measures − Health Assessment Questionnaire EuroQoL−5D questionnaires enrollment every 3 month . 3 . Plain Xrays − plain xrays hand , wrists foot baseline 18 month . Change Sharp score baseline 18 month film report 4 . Biomarker analysis − analysis include specific genetic factor ( genomic DNA ) , gene expression ( RNA analysis ) , novel autoantibody assay , cytokine / emerge inflammatory protein profiling , lipid / lipoprotein base marker , metabolic assay assessment bone cartilage turnover marker . Samples collect baseline , 3 month 12 month ( commence etanercept ) , immediately commence etanercept , 3 month 6 month commence etanercept 3 month cessation . Final disease outcome measure patient correlate baseline biomarker value determine predictive relationship exist . All value enter logistical regression analysis try create statistical predictive model . Serial biomarker analyse demonstrate different component pathogenetic process respond different stage DMARD therapy .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Synovitis</mesh_term>
	<criteria>1 . Patients attend Early RA clinic newly diagnose RA anti−CCP +ve Undifferentiated Arthritis ( UA ) 2 . Active disease ( DAS28 &gt; 3.2 ) 3 . DMARD naïve DMARD monotherapy le 6 week 4 . Aged 18 1 . Significant liver disease and/or abnormality liver function test 2 . AST / ALT &gt; x2 normal , Alkaline Phosphatase &gt; x2.5 normal 3 . Renal impairment − serum creatinine &gt; 200 μmol/l , eGFR &lt; 30 4 . Cytopenias − white cell count &lt; 4.0 , haemoglobin &lt; 10 , platelet &lt; 150 5 . Pregnancy plan pregnancy 6 . Contraindication MRI 7 . Other co−morbid condition opinion investigator would preclude use sequential combination DMARD therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Musculoskeletal Ultrasound</keyword>
	<keyword>Synovitis</keyword>
	<keyword>DMARD</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Undifferentiated Inflammatory Polyarthritis</keyword>
</DOC>